Dinosaur-era flying reptile's fossil reveals first direct evidence of plant diet
The fossil belongs to a species of pterosaur called sinopterus atavismus, unearthed in northeastern China. According to the study, its stomach contained phytoliths—tiny, rigid mineral structures produced by plants—suggesting it had been feeding on vegetation.
Scientists also found small quartz crystals, which the reptile may have ingested to help break down its food, similar to modern birds that swallow stones for digestion.
Prehistoric flying reptile had stones and plants in its stomach
For millions of years before birds took to the skies, pterosaurs dominated the airspace as the first vertebrates to achieve powered flight. These extinct flying reptiles lived from the Late Triassic period about 240 million years ago until the end of the Cretaceous period around 66 million years ago. While often mistaken for dinosaurs, species such as pterodactyls and pteranodons belonged to their own distinct group.
"The first occurrence of phytoliths, associated with gastroliths, in the stomach contents confirms the herbivory of Sinopterus. It is the first time that such structures have been discovered in pterosaurs," the team behind the study stated in the research paper.
Researchers from the Institute of Vertebrate Palaeontology and Paleoanthropology (IVPP) at the Chinese Academy of Sciences informed that among the several questions surrounding these flying reptiles is their dietary habit, which remains poorly understood, the South China Morning Post reported.
The team explained that scientists have long debated what pterosaurs ate, with theories ranging from insects, fish, meat and plants, and even the possibility that some species filter-fed like whales—an uncertainty that has persisted because fossilized evidence of their meals is extremely rare.
Fossil preserved in shale slab, captured delicate details
Although paleontologists have studied pterosaur fossils for decades, only five confirmed cases of stomach contents have been identified in earlier, non-pterodactyloid species and those mostly contained fish remains.
The exceptionally rare, nearly complete specimen of sinopterus was unearthed by researchers from IVPP in China's Liaoning province, within a Lower Cretaceous geological formation. This species belongs to the tapejaridae family, a group of toothless pterosaurs. The fossil was preserved in a fine shale slab, a type of compacted mudstone known for capturing even the most delicate details of ancient life.
The research team, which included experts from Shenyang Normal University and the National Museum of Brazil, used specialized 3D X-ray imaging to analyze the fossil.
Inside the body cavity, the team found a fine, claylike material that looked like undigested plant matter. This material contained tiny rigid structures known as phytoliths, which form inside plant cells and can survive long after the rest of the plant has decayed.
According to David Martill, a paleontologist at the University of Portsmouth who was not involved in the research, this extraordinarily rare discovery—the kind that happens once in a century—overturns the long-held belief that these fierce-looking winged reptiles were purely carnivorous.
You can view the study here.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
2 hours ago
- Gizmodo
Non-Hormonal Male Birth Control Pill Passes Key Test
For many couples, the numerous options for birth control still come with plenty of hassles. But scientists are working on an alternative approach that might be more appealing for some: a non-hormonal male birth control pill with possibly very few side effects. The drug is codenamed YCT-529, and it's being developed by the company YourChoice Therapeutics, in conjunction with researchers from the University of Minnesota and others. In early human trial results published this week, YCT-529 appeared to be safe and tolerable. The drug is now being tested in larger-scale studies. Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup YCT-529 (previously known as GPHR-529) targets how the body interacts with vitamin A, which helps maintain fertility in mammals. It blocks a protein that binds to a form of vitamin A (retinoic acid) in our cells, known as retinoic acid receptor alpha (RAR-α). By selectively blocking RAR-α and not other similar proteins, the hope is that YCT-529 will reduce sperm production to zero without causing any major side effects. Importantly, this process is also meant to be reversible once people stop taking the drug. The company began its first clinical trial of YCT-529 in late 2023, and the findings of the trial were published this week in Communications Medicine. It involved 16 healthy men who received either a daily placebo or varying doses of YCT-529; some were also given the drug in combination with food. Phase I trials are primarily intended to test a drug's safety, and YCT-529 seemed to pass with flying colors. Compared to controls, the men on YCT-529 experienced no changes in their heart rate, sex drive, mood, or levels of fertility-related hormones. In fact, no adverse events likely related to the drug were documented at all, the researchers found. There was some evidence that food might slow people's absorption of the drug, though more study is needed to know for sure. 'These results warrant further clinical development of YCT-529,' the study authors wrote. With a New Gel, the Future of Male Birth Control Looks Bright As promising as this data looks, it is still very early days. That said, YourChoice Therapeutics has already forged ahead with a larger Phase II study of YCT-529. And the race to create the world's first reversible male birth control is only heating up. Other research teams and companies have developed contraceptive gels and implants that have also shown promise in human trials so far. Soon enough, men will hopefully have several birth control options to pick from, just like women.

Wall Street Journal
2 hours ago
- Wall Street Journal
A Cosmic Mystery: Is China Building the World's Biggest Telescope?
Astronomer Robert Kirshner investigates some of the universe's biggest questions: What happens when a star explodes? Is the universe still expanding? He recently added a new mystery to the list: Is China quietly building the world's biggest telescope? He would like to know, because he leads a rival telescope project in the U.S.
Yahoo
3 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know